Drugs / GTx-758
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01615120 | Aug 2012 → Nov 2016 | prostate cancer | GTx | Completed | No outcome recorded |
| Phase 2 | NCT01420861 | Sep 2011 → Dec 2012 | prostate cancer | GTx | Terminated | No outcome recorded |
| Phase 2 | NCT01393119 | Aug 2011 → Dec 2012 | prostate cancer | GTx | Terminated | No outcome recorded |
| Phase 2 | NCT01326312 | Jun 2011 → Dec 2012 | prostate cancer | GTx | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTx-758 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01393119 ↗ |
| Known as | Capesaris | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545017 ↗ |
| Action | Activate | “GTx-758 is a nonsteroidal selective ER agonist” NCT01326312 ↗1“Estrogen receptor alpha agonist” CHEMBL3545017 ↗ |
| Modality | Small molecule | “3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide” NCT01393119 ↗ |
| Route | Oral | “one GTx-758 tablet orally administered daily” NCT01615120 ↗ |
| Target | ESR1 | “Estrogen receptor alpha agonist” CHEMBL3545017 ↗ |